IQVIA Holdings Inc.


SKU: IQV-1 Category:


IQVIA Holdings Inc.: Clinical Trials and AI Enablement As A Major Growth Catalyst!


On the positive side, the company delivered top and bottom-line numbers either on or slightly above the expectations. The favorable demand for the industry continued to surge as IQVIA’s revenue grew by 6%. The clinical side of the business, in particular, saw solid demands from R&DS clients, which boosted their backlog to a new record, growing almost 8% compared to the prior year. A notable achievement was the net new bookings for the quarter which was approximately $2.6 billion. This showcased a strong quarterly book-to-bill of 1.23 despite a substantial cancellation in the CNS area. IQVIA also continued its strategic partnerships and secured contracts with various clients, consequently broadening its market reach.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!